



TRT Announces Exclusive License Agreement with Acoustic Wave Cell Therapy, Inc. (AWCT)

Woodstock, GA, April 19, 2016 – Tissue Regeneration Technologies, LLC (TRT) announces an Exclusive License Agreement with **Acoustic Wave Cell Therapy, Inc. (AWCT)**, a Delaware Corporation, whereby **AWCT** will utilize **TRT's** extensive patent portfolio to develop and market low energy acoustic wave treatments for multiple internal organs and associated tissues and pathologies.

AWCT's founder and Chief Medical Officer is Dr. Tom Lue, a renowned researcher and clinician, and Professor of Urology at the University of California San Francisco (**UCSF**) for over 30 years. **UCSF** is home to one of the world's premier medical centers and is the leading public recipient of biomedical research grants from the National Institutes of Health. Five of its researchers have received the Nobel Prize in Medicine and Physiology. Dr. Lue and his research team have spent the last five years working with **TRT** technology at **UCSF** to develop optimized protocols to treat different tissue types and organs in preclinical studies. In their **UCSF** research laboratory, they have successfully regenerated damaged tissues in various organs in animals and established the safety of their protocols.

AWCT has obtained from **UCSF** an exclusive license to the patent rights associated with Dr. Lue's discoveries. **AWCT** will now take over the clinical development and do all work necessary to obtain FDA approval for these treatments. Therapeutic targets include diseases of the liver, kidney, urinary tract and pancreas.

John Warlick, **TRT's** CEO, stated: "**TRT** is pleased to be a shareholder in this new venture as well as the licensor of the technology. We will work closely with **AWCT** to guarantee the mutual success of both **AWCT and TRT**. This is an exciting day for our employees, researchers, patients and shareholders -- all of whom we thank for their continued support."

Charles Engles, **AWCT's** CEO stated: "**TRT** has been a visionary in recognizing the vast therapeutic potential of low energy acoustic waves and has assembled the largest patent portfolio in the industry. We are pleased to be able to work with **TRT** to commercialize this technology and make low energy acoustic wave therapy the standard of care for the treatment of specific internal organ disorders."

See www.trtllc.com for the latest about TRT.

TRT Contact
John Warlick
(404) 402-6844

AWCT Contact
Charles Engles
(650) 851-7358